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Abstract. Isoform-specific antibodies to TGF01,
TGF02, and TGF03 proteins were generated and have
been used to examine the expression of these factors
in the developing mouse embryo from 12 .5-18.5 d
post coitum (d.p.c.). These studies demonstrate the
initial characterization of both TGFs2 and /33 in mam-
malian embryogenesis and are compared with TGF01.
Expression of one or all three TGFO proteins was ob-
served in many tissues, e.g., cartilage, bone, teeth,
muscle, heart, blood vessels, lung, kidney, gut, liver,
eye, ear, skin, and nervous tissue. Furthermore, all
three TGFO proteins demonstrated discrete cell-specific
patterns of expression at various stages of development
and the wide variety of tissues expressing TGF0 pro-
teins represent all three primary embryonic germ lay-
P
OLYPEPTIDE growth factors such as the 0-type trans-
forming growth factors (TGFos) mediate many cell-
cell interactions that occur during embryonic devel-
opment (reviewed in Mercola and Stiles, 1988; Whitman and
Melton, 1989; Nilsen-Hamilton, 1990). Complementary
DNA clones havebeen isolated for five TGFS species (TGFos
1-5); however, purified or recombinant protein has been ob-
tained only for TGF$s 1-3 (Derynck et al., 1985, 1988;
Madisen et al., 1988; ten Dijkeet al., 1988; Jakowlew et al.,
1988). Moreover, only TGFos 1-3 have been found in mam-
mals. The molecular structures of TGF01, (32, and 03 are
very similar in that each polypeptide is synthesized as a pre-
pro monomeric protein and is cleaved to yield a 112-amino
acid polypeptide that remains associated withthe latent (pro)
portion ofthe molecule (reviewed in Lyons and Moses, 1990
or Miller et al., 1990) . Biologically active TGF0 protein re-
sults from dimerization of the monomers (usually homodi-
mers) and release of the latent peptide portion. Overall, the
mature region of the TGF03 protein has -80% identity to
the mature regions of both TGFO 1 and TGF02, however, the
NH2-terminal or precursor regions of these three molecules
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ers. For example, specific localization of TGFS1 was
observed in the lens fibers of the eye (ectoderm),
TGFS2 in the cortex of the adrenal gland (mesoderm),
and TGF03 in the cochlear epithelium of the inner ear
(endoderm). Compared to the expression of TGFO
mRNA transcripts in a given embryonic tissue, TGFO
proteins were frequently colocalized within the same
cell type as the mRNA, but in some cases were ob-
served to localize to different cells than the mRNA,
thereby indicating that a complex pattern of transcrip-
tion, translation, and secretion for TGFss 1-3 exists in
the mouse embryo. This also indicates that TGF01,
02, and ,83 act through both paracrine and autocrine
mechanisms during mammalian embryogenesis.
share only 27% sequence identity (ten Dijke et al., 1988;
Derynck et al., 1988). Some differences in the in vitro bio-
logical activities of TGF01 and TGF02 have been reported
(Ohta et al., 1987; Jennings et al., 1988; Rosa et al., 1988;
Merwin et al ., 1991), however, in general, TGFos 1, 2, and
3 have qualitatively similar activities when added to cellsin
culture (Graycar et al., 1989) . In addition, competition stud-
ies with TGF,S1, TGF02, and TGFS3 suggest that these pro-
teins interact with the same cell-surface binding molecules
(Graycar et al., 1989), although in some cell types, a given
TGFO isoform may preferentially bind to an individual sub-
set of these presumptive receptors (Segarini, 1990).
In recent years, several converging lines of evidence have
indicated that members of the TGFO family play important
roles in many different embryonic processes (reviewed in
Akhurst et al., 1991 or in Pelton and Moses, 1990a). For
example, in vitro TGFRsare mitogenic for cellsderived from
supporting tissues such as bone and cartilage but are inhibi-
tory for many other cell types. The TGF0s also regulate
differentiation (which may be stimulatory or inhibitory de-
pending on the cell type), stimulate extracellular matrix
deposition, are chemotactic for certain cells, and induce
mesoderm formation during early embryogenesis. In an at-
temptto elucidate the in vivo activities ofthe TGFos, we andothers have investigated the expression patterns of TGF#
genes during embryonic development and a number of
studies have now described the in vivo localization of
mRNAs for TGFOs 1-3 during murine embryogenesis (Leh-
nert and Akhurst, 1988; Pelton et al., 1989, 1990a,b; Ak-
hurst et al ., 1990; Miller et al., 1990; Fitzpatrick et al.,
1990; Millan et al., 1991; Schmid et al., 1991) . Recently we
used in situ hybridization to directly compare the localiza-
tion of TGFO1, /32, and /33 mRNA transcripts in the mouse
embryo (Pelton et al., 1990a,b). During mid to late embryo-
genesis, the murine TGFss 1-3 were shown to have overlap-
ping but distinct patterns of mRNA expression. These pat-
terns changed as development progressed and were often
found in tissues undergoing morphogenetic alterations. For
example, during the development of the whisker follicles of
the mouse, the mRNA expression patterns for TGFOs 1-3
were all differentin the immature follicle but were very Simi-
lar in the mature follicle (Lyons et al., 1990). In situ hybrid-
ization studies with human embryonic tissue have produced
results similar to those obtained with mouse embryos (Sand-
berg et al., 1988a,b; Gatherer et al., 1990) .
Although in situ hybridization experiments designate which
cells and tissues synthesize mRNA transcripts for a given
gene, these studies cannot determine ifthe mRNAs are trans-
lated into proteins; hence the relative amount of mRNA may
not reflect similar amounts of protein. This phenomenon
may have particular relevance in the study of TGFO expres-
sion. For example, Madisen et al. (1988) demonstrated that
a humanprostatic adenocarcinoma cell line produces higher
levels of TGF01 and TGF02 mRNA but significantly higher
levels of TGF02 than TGF01 protein. In addition, because
the TGF,Bs 1-3 are secreted proteins, TGFO mRNAs may not
colocalize with TGFO proteins. Indeed, by comparing their
in situ hybridization studies with published immuno-
histochemistry data (Heine et al., 1987), Akhurst and co-
workers have already shown this to be true for TGF01
mRNA and protein (Lehnert and Akhurst, 1988; Akhurst et
al., 1990, 1991) .
Using isoform-specific antibodies for TGFO1, 02, and (33,
we have investigated the expression of TGFO proteins in the
mouse embryo and compared the distribution of these pro-
teins with their respective mRNAs. Our results show that
TGFOs 1-3 are expressed in unique temporal and spatial pat-
terns in a wide range of embryonic tissues, suggesting that
these factors play multiple roles during morphogenesis and
organogenesis. Moreover, when compared with the TGFO in
situ hybridization studies, the data presented here indicate
that all three mammalian forms of TGFO (,Q1, 02, and (33)




Staged embryos (Theiler, 1989) were obtained frommatings ofICRoutbred
female (Harland Sprague Dawley) and Swiss-Webster male mice (Taconic
Farms, Germantown, NY). Noon onthe day of vaginal plug was considered
0.5 days p.c. Pregnant females were killed via cervical dislocation and the
12.5-18.5 d.p.c. embryos were placed immediately in ice-cold 4% parafor-
maldehyde/PBS.
Antibody Preparation
Peptides ofeach TGF(3 isoform were synthesized using a 430A peptide syn-
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thesizer (Applied Biosystems, Inc., Foster City, CA), incorporating the
t-boc solid phase synthesis method followed by hydrofluoride cleavage. The
following amino acid residues were used: TGF,61 and TGF02, residues
4-19; TGF03, residues 9-20. The peptides were purified by high pressure
liquid chromatography using a gradient composed of 0.1% trifluoracetic
acid and 100% acetonitrile. Each peptide (5.0 mg) was dissolved in 0.1 M
NaHC03 and coupled to KLH at a 1:1 ratio (wt/wt), by adding 3-ul vol of
1.25% glutaraldehyde 10 times over a period of 3 h. Rabbits were initially
immunized with 500ugofeach peptide and subsequently boosted with 250
rug every2.5 wk. Antibody titerwas determined by ELISA using the appro-
priate corresponding uncoupled peptide and alkaline phosphatase goat
anti-rabbit IgG as the second antibody (Promega Biotec, Madison, WI).
The antisera did not cross-react with the TGFO peptides that were not used
as immunogen. Each antiserum was purified by ammonium sulfate precipi-
tation (31.3%), followed by affinity chromatography using the respective
immunogenic peptide. The peptide (8.0 mg) was coupled to 2 ml of Tresyl-
Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) overnight accord-
ing to the manufacturer's instructions. The purified IgG was eluted with 50
mM glycine (pH 2.5) into Tris buffer (pH 7.2) for neutralization, dialyzed
against TBS, aliquoted, and stored frozen. Each antipeptide antiserum was
tested for both immunoreactivity with the corresponding mature isoform of
the TGF(3 molecule and for cross-reactivity with each other TGFO isoform
by Western blot analysis.
Western Blot Analysis
Recombinant human TGFS1 and TGF,83 were generously provided by Dr.
Michael Palladino and Dr. Rik Derynck, respectively, of Genentech, Inc.
(PaloAlto, CA). Native porcine TGF02 was purchased from R &D Systems
(Minneapolis, MN) . Human and porcine TGFO amino acid sequences are
identical. Each TGFO molecule was reduced with a final concentration of
0.1 M DTT, subjected to SDS-PAGE using a gradient polyacrylamide gel
of 10-20% and subsequently transferred to a nitrocellulose membrane for
1 h at 100 V using the Biorad Miniblot System (Bio-Rad Laboratories,
Cambridge, MA). The membranes were blocked with 3 % non-fat dry milk
in TBS (0.01 M Tris, 0.15 M NaCl, pH 8.0) for 1 h and directly incubated
overnight in purified anti-peptide IgG in TBS containing 0.1% 'Iween 20
(TBST) at the following dilutions: TGF#1, 1:50; TGF#2 and TGFS3, 1:25.
The membranes were washed with TBSTand incubated with alkaline phos-
phatase-labeled goat anti-rabbit IgG (Promega Biotec) at a dilution of
1:3,000 for 1 h. The blot was developed with NBT/BCIP (Promega Biotec).
Immunohistochemistry
The protocol used for these studies was a modified version of the method
reported in Heine et al. (1987). Tissues were fixed overnight in 4% parafor-
maldehyde/PBS, dehydrated in increasing concentrations of ethanol, and
embedded inparaffin wax (Fischer Scientific Co., Pittsburgh, PA). Sections
of 5-7 lum were cut and floated onto slides coated with 3-triethoxysilyl-
propylamide (Sigma Chemical Co.). The sections were submerged in TBS/
0.1% (vol/vol) Triton X-100 at room temperature for 15 min followed by
TBS for 5 min, methanol for 2 min, and methanol/0.6% (vol/vol) hydrogen
peroxide for 30 min. Slides were subsequently washed atroom temperature
inmethanol for 2 min, TBS for 5 min, and three times in TBS/0.1% (wt/vol)
BSA for 3 min. After treatment with hyaluronidase (1 mg/ml in 100 mM
sodium acetate, 0.85% (wt/vol) NaCl) and three washes in TBS/0.1% BSA,
excess protein was blocked with 5% normalswine serum in TBS/0.5% BSA
for 15 min at room temperature. Tissue sections were incubated with pri-
mary antibodies at a concentration of 5 pg/ml (diluted in TBS containing
5 % swine serum and 0.1 % BSA) overnight at 4°C. Control slides were in-
cubated with either an IgG fraction of normal rabbit serum at 5 ug/ml
(diluted in TBS containing 5 % swine serum and 0.1 % BSA) or without pri-
mary antibodies. Tissues werethenwashed in TBS/0.1% BSA and incubated
for 60 min at room temperature with biotinylated swine antirabbit second-
ary antibody in TBS/0.1% BSA. After washes in TBS/0.1% BSA, the sec-
tions were exposed to avidin-biotin complex for 60 min at room tempera-
ture and again washed in TBS/0.1% BSA. Slides were reacted with 0.05%
(wt/vol) DAB in 50 mM Tris-HC1 (pH 7.4) with 0.1% (vol/vol) hydrogen
peroxide for 5 min and counterstained in haematoxylin.
Results
Antibody Specificity
Western Blot Analysis. The specific immunoreactivity of
1092Figure 1. Western blot analysis demonstrating the specificity of
TGFO antipeptide antibodies. Recombinant TGFSI and TGFfl3
proteins and porcine platelet TGF02 (50 ng each) were electropho-
resed and transferred to nitrocellulose . Each TGFfl protein was
reacted with each antiserum to TGFO overnight . Dilution for an-
tisera/anti-TGFS1 was 1:50 ; and 1:25 for anti-TGF,B2 and anti-
TGF/33. Molecular weight markers are shown on the right .
each antipeptide antiserum with its respective TGFf isoform
was demonstrated by Western blot analysis as depicted in
Fig . 1 . Each purified IgG to TGF#1, (32, or S3 reacted only
with the appropriate and corresponding native or recombi-
nant molecules-(50 ng) offMFOI (Fig . l, lane 1), TGFf22
(Fig . 1, lane 2), or rTGFs3 (Fig. 1, lane 3) . No cross-
reactivity was observed among any of the TGFIB isoforms.
The specificity ofthe individual antisera was further demon-
strated after complete absorption of the immunoreactivity
with 10 M excess of the corresponding peptide (data not
shown) . Lastly, the ability ofthe antipeptide antibodies to re-
act (but not cross react) on a Western blot with the appropri-
ate native TGFfll, TGFft2, and TGFS3 molecules purified
from human umbilical cord tissue further suggests that these
antibodies are specific for their respective proteins (L . I .
Gold, manuscript in preparation) .
Immunohistochentistry . 'Ib ensure the specificity of the
anti TGFS antisera for immunohistochemical studies, serial
tissue sections were used for control and experimental
slides . Control slides were reacted with either (a) the IgG
fraction of normal rabbit serum (at the same concentration
as the primary antibody) in place of the peptide antibodies ;
or (b) no primary antibody. Fig . 2 shows examples ofcontrol
sections directly compared against experimental sections .
The epidermis and hair follicles in the skin of a 17.5 d.p.c .
mouse showed strong immunoreactivity with TGFSI anti-
bodies (Fig. 2 B), while absolutely no staining was observed
with normal rabbit IgGs (Fig . 2 A) . Similarly, while the ker-
atinized epithelium of the palate and tongue of a 17.5 d.p.c
embryo showed intense staining with TGFSI antibodies, no
staining was observed using the normal rabbit IgGs (com-
Figure 2 . Comparison of embryo sections incubated with either normal rabbit IgGs or with antibodies to TGFS1 . (A and B) Section of
17.5 d.p .c . mouse skin incubated with normal rabbit IgGs (A) or with TGFS1 antibody (B) . Staining is seen only in the epidermis and
hair follicles ofB. (C and D) Section through the oral region of a 17.5 d.p .c . mouse embryo incubated with normal rabbit IgGs (C) or
with TGFO1 antibody (D) . Staining is seen only in the keratinized epithelium of the palate and tongue ofD . e, epidermis ; d, dermis ;
f, follicle ; b, bone ; t, tooth ; tg, tongue ; p, palate . Bars : (A) 35 Am ; (C) 175 Am ; (D) 55 Am .
Pelton et al . TGFO Protein Expression during Mouse Development
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1093Table L Embryonic Cell Types Expressing TGFO Proteins
Immunolocalizafion of TGFpl, 62, and 03 proteins in the 12.5-18 .5 d .p .c .
mouse embryo. A + indicates that positive staining was seen in this tissue at
some stagebetween 12 .5 and 18.5 d .p .c., while a - means that no staining was
detected. The number of + signs denotes relative intensity of staining when
compared against the other TGFO antibodies inthat particular tissue and should
not be compared against the staining intensity in other tissues . See text for a
more detailed description of the temporal and spatial expression patterns . To
compare the itnmunohistochemical expression of TGFO proteins with TGFO
RNAs, the reader is referred to Table I of Millan et al . (1991) .
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pare Fig . 2, D with C) . Although the control data for each
tissue is not shown, in all cases examined the control slides
were negative .
Immunohistochemical Localization ofTGFO Proteins
The results of the immunohistochemical localization of
TGFss 1-3 are summarized in 'Fable I . Data not shown in
Figs. 2-11 are referred to in Table I .
The Embryonic Skeletal System . Chondrification centers
for most bones are first seen in the embryo at -13-14 d.p.c.
with centers of ossification usually appearing 2-3 d later
(Rugh, 1990) . At 12 .5 d.p.c., chondrocytes in the ribs and
vertebrae showed strongTGF03 staining but only veryweak
staining for TGFOI or TGF02 . The cartilage rudiments in
other bones at 12.5 d.p.c . showed little TGF03 staining.
From 13.5 to 15.5 d.p.c ., TGF03 staining in the chondro-
cytes remained high and as the maturing chondrocytes be-
came hypertrophic, TGFO1 (Fig . 3, A and B) and TGF02 ex-
pression was seen . TGF01 levels were especially high in the
perichondrium (Fig. 3, A and B) . By 16.5 d.p.c., high levels
ofTGFOI were localized to the periosteum of several bones
(Fig . 3, C and D) as well as in the maturing chondrocytes
of various cartilage rudiments . Although little TGF02 or
TGF03 was detected in the periosteum, both were found in
osteocytes ofbone and maturing chondrocytes such as those
of the tracheal cartilage . The TGF03 staining in bone was
found in the cytoplasm of osteocytes, while theTGF02 stain-
ing was found predominantly in the extracellular matrix sur-
rounding the osteocytes (Fig . 3 E) . TGF(31 immunoreac-
tivity in the 17.5 d.p.c . embryo was found in the developing
maxilla (Fig. 3 F), an intramembranous bone, as well as in
the periosteum of endochondral bones (Fig . 3, C and D) .
Whereas TGF,61 and TGF,62 were both still present at high
levels in osteogenic bone and hypertrophic cartilage at this
stage, TGF03 staining had diminished (Fig . 3, C-F) .
It has been previously demonstrated that at 16.5 d.p.c .,
very high levels ofTGFOmRNAs are found in the embryonic
tooth, primarily in the odontoblast and mesenchymal pulp
cells (Pelton et al ., 1990x) . However, TGFO proteins in the
17.5 d.p.c . tooth were localized to additional structures . For
example, although TGFO1 mRNA was very abundant in the
pulp cells, TGFSI antibody staining was seen at highest lev-
els in the ameloblast layer (Fig . 3 G) . In addition, while
TGF02 mRNA was found at high levels in the odontoblast
layer and to a lesser extent in the pulp cells, TGF02 protein
was observed at high levels in both the odontoblast and pulp
cells (Fig . 3 H) . TGF03 immunostaining was found at low
levels in both the pulp cells and the ameloblasts but was not
seen in the odontoblast layer.
Tote Embryonic Circulatory System. Previous reports have
shown that at 7 d.p .c ., TGFO1 mRNA was observed in car-
diac mesoderm cells ; however, TGFOI protein could not be
detected (Akhurst et al ., 1990) . Transcripts for TGF03 are
restricted to the atrioventricular cushions of the 11.5 d.p.c .
heart and are not found in the ventricles (Pelton et al.,
1990x) . Although immunostaining for TGF#3 protein, and
to a lesser extent for TGF0l and TGF02, was also present
in the embryonic heart from 12.5 through 16.5 d.p.c ., as seen
in the tooth, there were differences in the TGFO mRNA and
Figure 3. Localization ofTGFR proteins in the murine embryonic skeletal system . (A) Cross section through the ribs of a 14.5 d.p .c. embryo
stained with TGFS1 antibodies. Staining is seen primarily in the perichondrium surrounding the hypertrophic cartilage in the ribs . (B)
Higher power magnification ofA, illustrating high TGF(31 expression in the perichondrium of a rib. Lower levels were seen in the hyper-
trophic cartilage . (C) Longitudinal section of a bone atthe base ofthe skull in a 17.5 d.p .c . embryo stained with TGF/31 antibodies. TGF01
Cell type TGFOl TGF132 TGF03
Cartilage
perichondrium + + + + ++
chondrocytes + + + + +
Bone
periosteum + + - +
osteocytes + + + + + +
Tooth
ameloblasts + + - +
odontoblasts - ++ -
pulp + +++ +
Muscle
smooth + + + +
cardiac + + + ++
skeletal + + + +
Heart
endothelium - - -
myocytes + + +++
Lung
bronchi + + + + + +
alveoli - - -
Blood vessels
endothelium - - + +
smooth muscle + + + + +
Kidney
tubules + + ++ + +
basement membrane - + + + -
Adrenal
cortex +++ +++ -
medulla - - -
Gut
esophageal epithelium +++ + +
stomach epithelium + + + + +
intestinal epithelium + + + +
basement membrane - + + + -
muscularis + + + +
Liver
capsule - - + +
parenchyma - - -
megakaryocytes + - ++
Eye
lens epithelium - - -
lens fibers + + + + +
Ear
cochlear epithelium - + + + +
basement membrane - + + + -
CNS
meninges + + ++ +
glia - + + + +
choroid plexus - - + +
Skin
periderm + + + + +
epidermis + + + + ++ + + +
dermis + + + + +
hair follicles + + + + +is seen in the periosteurn (arrow)andosteogenic zone of thebone. (D) HigherpowerofCshowing theTGFOI expression inthe periosteurn
of thebone (arrow) .QSame bone as in Cstained with TGF#2 antibodies . Staining is seen in the hypertrophic cartilage and osteogenic
zone of the bone . (F) Staining with TGFOI antibodies in osteoblasts in the maxilla of a 17.5 d.p .c . embryo. (G) Section through a tooth
in a175dT .c . embryo incubated withROW antibodies . Staining is seen in the basal region ofthe ameloblasts (arrow). (H)Same section
as in G incubated with TGF02 antibodies . Staining is seen in the odontoblasts (arrow)and in the mesenchymal pritnordium of the pulp.
r, ribs; c, cartilage; pc,perichondrium; br, brain; o, osteogenic zone (D andE) ; h, hypertrophic cartilage; m, maxilla ; p, palate; a, amelo-
blasts ; mp, mesenchymalprimordiurn of the pulp ; o, odontoblasts (H) . Bars: (A) 110 urn; (B) 30 jum; (C) 120 gm; (D) 65 Am; (E) 115
Arn; (F) 145 Vim; (G) 80 gym; (H) 80 gm .
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1095Figure 4 . Expression ofTGFS3 in the 12 .5 d.p.c . embryonic circulatory system . (A) Parasagittal section through a 12.5 d.p .c . heart stained
with TGF03 antibodies . Staining is seen in the atria and ventricles . (B) Sagittal section through same heart as in A illustrating TGF03
in the walls of the aorta and at low levels in the atrioventricular cushions (arrow), (C) Section showing TGF03 localization in an umbilical
vessel (arrow) . (D) TGF03 staining in an embryonic blood vessel (arrow) near the spinal cord . a, atria; v, ventricle ; 1, liver ; ao, aorta ;
av, atrioventricular valve ; uv, umbilical vessel ; sc, spinal cord ; bv, blood vessel ; c, cartilage . Bars (A) 175 pm ; (B) 175 'm ; (C) 115 um ;
(D) 60 um .
protein expression patterns in this tissue. For example, while
TGF03 mRNA signal was high in the atrioventricular
cushions and low in the ventricles of the 11.5 d.p.c . mouse
heart, TGF03 protein in the 12 .5 d.p.c. heart was high in the
ventricles and atria and low in the atrioventricular cushions
(Fig . 4, A andB) . By 17.5 d.p.c ., the staining forTGF01 and
TGF(32 proteins was barely detectable above background
while TGFQ3 staining remained strong. TGFO 1-3 staining
was also found in blood vessels throughout the body. For ex-
ample, TGF03 immunoreactivity was found in small vessels
such as those entering the spinal cord (Fig . 4 D) as well as
in large arteries and veins, such as the umbilical and pulmo-
nary vessels (Fig . 4 C and 8, A and B) .
The Embryonic Internal Organs . Thompson et al . (1989)
have shown thatTGF01 is localized to a subset oftubule cells
in the cortex of the adult kidney and in the present study,
TGFO proteins were also found in the embryonic kidney
(Fig . 5,A-D) . In the 12 .5 d.p .c . embryo, the developing kid-
ney consists of metanephric tubules lined by a cuboidal epi-
thelium (Rugh, 1990) . At 12 .5 d.p.c ., TGF02 staining was
present in a very restricted pattern in the basement mem-
brane of the cuboidal epithelium . Neither TGFS1 nor TGF,53
was detected in the kidney at this stage . From 13.5 to 14.5
d.p.c ., the TGF#2 expression in the basement membrane of
the cuboidal epithelium increased in intensity and became
more extensive (compare Fig . 5, A and B) . In contrast, dur-
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ing this stageTGF#l andTGF03 were found in the cuboidal
epithelial lining ofthe tubules, but not in the basementmem-
branes . The expression ofTGF01 and (33 remained high in
the tubule epithelium throughout development . TGF02 stain-
ing was found in the basement membrane surrounding the
tubules throughout development, but was also detectable in
the tubule epithelium beginning at 15.5 d.p.c. (Fig . 5, C and
D) in a pattern similar to TGFO1 and TGF03 . Although the
staining intensity for all three TGFos in the tubular epithe-
lium of the kidney began to decrease at 17.5 d.p.c ., immu-
noreactivity for TGF01s 1-3 in the mesenchymal cells that
support the tubules could be seen at this stage .
TGF01 has been previously localized to the zona fasiculata
and zona reticularis in the cortex ofthe adult murine adrenal
gland (Thompson et al ., 1989) . Similarly, in our studies, the
embryonic adrenal gland also shows very strong TGFO im-
munoreactivity . Adrenal blastemas are present in the 11
d.p.c. embryo, but these do not consolidate into cortex and
medulla until 14 d.p.c . (Rugh, 1990) . Antibodies to TGFM
and TGF02 showed only slight reactivity in the 13.5 d.p.c.
embryos ; however by 15.5 d.p.c., very strong staining for
TGF02 (Fig . 5, C, E, and F) and TGFO1 was present in the
cortex (presumptive zona fasiculata and zona reticularis) of
the adrenal gland . This high level of expression for TGF01
andTGF02 persisted through 17.5 d.p.c . . Antibody staining
was confined to the cortex since the medulla was negative for
1096Figure5 . TGF02 localization in the embryonickidney and adrenal gland. (A )13.5 d.p .c . kidney showingTGF02 at the base ofthe epithelium
in a subpopulation of tubules (arrows) . (B) 14.5 d.p .c . kidney demonstrating TGF02 staining similar to that in (A). At 14.5 d.p.c ., the
staining is stronger and in almost all tubules of the kidney cortex (arrows) . (C) Section through a 15.5 d.p .c . kidney and adrenal gland
showingTGF02 localization in kidney tubules and cells of the adrenal cortex . (D) Higher power ofthe kidney in Cshowing TGFS2 staining
in the epithelium of the kidney tubules as well as in the supporting cells at the base of the epithelium (arrows) . (E) TGF02 expression
in the cortex of a 15 .5 d.p .c . adrenal gland . The medullary cells show no TGF02 staining . (F) Higher power of the section inE showing
TGF02 staining in the cells of the adrenal cortex but not the adrenal medulla . k, kidney ; a, adrenal gland; t, kidney tubule ; m, adrenal
medulla ; c, adrenal cortex . Bars : (A) 120 Am ; (B) 125 Am ; (C) 200 Am; (D) 35 Am; (E) 125 Am ; (F) 40 Am .
TGFO1 and /32 immunoreactivity (Fig. 5,Eand F) . TGF03
didnotappear to be present in the adrenalglandduring these
stages of development (13.5-17.5 d .p .c .) .
Using sequential elution of intestinal villus cells and
Northern blot analysis, Barnard et al . (1989) have demon-
strated that TGFO1mRNA is present in a gradient along the
villi epithelium in the adult rat intestine with highest levels
evident at the tipof the intestinal villus. Immunohistochem-
istry reflects a similar gradient ofTGFO proteins in the em-
bryonic gut. Slight reactivity was seen at 14 .5 d.p.c . in the
Pelton et al . TGFS Protein Expression during Mouse Development
intestinal epithelium with all three TGFO antibodies, butby
15.5 d.p.c. significantly stronger staining in these cells was
observed (Fig . 6 A) . Similar to the TGF01mRNA localiza-
tion, staining appeared inagradient fashionwith thehighest
levels of TGFO proteins at the villus tip ; lowest levels were
in the intestinal crypts . Although TGFO1 staining remained
high at 17.5 d.p.c . (Fig . 6 B), TGF02 and TGF03 staining
was not as intense as seen during earlier stages . In addition,
the stratified squamous epithelium ofthe esophagus and fore-
stomach in the 17.5 d.p.c. embryo showed intense TGFO1
1097Figure 6. Expression ofTGF#1 and TGF02 in epithelia of the embryonic digestive tract. (A) TGF#I expression in the villi of the 15.5
d.p.c . intestine. Staining is highest at the villus tip (arrow) and lowest in the crypts. (B) Sectionthrough the 17.5 d.p.c . intestine showing
TGFOI staining in the villi. Staining is similar to that inA. (C) Localization of TGFfll in the squamous epithelium (arrow) of the 17.5
d.p.c. esophagus . (D) TGFO1 expression in the squamous epithelium of the forestomach of a 17.5 d.p.c. embryo . g, gut; vt, villus tip;
c, crypt; e, esophagus ; m, muscle; fs, forestomach . Bars : (A) 80 um ; (B) 75 prn; (C) 50 fcm; (D) 95 Am .
Figure 7 Localization of TGF(3 proteins in thesubmucosa oftheembryonic stomach, intestines and in the liver capsule. (A) Section through
a 13.5 stomach showing TGF02expression in the submucosa) region just basal to the epithelium (arrow) . (B) Higher powerofthe section
inA showingTGF82 staining in thesubmucosa(arrow). (C) Section demonstrating TGF022 localization in thesubmucosa of the 15.5 d.p.c.
intestine (arrows) . (D) Expression ofTGF03 in the capsule (arrow) of a 13.5 d.p.c. liver . Low levels ofTGF03 staining were also seen
in the mesenchymal cells supporting the liver parenchyma . g, gut; e, epithelium ; sm, submucosa ; lc, liver capsule; lp, liver parenchyma.
Bars : (A) 90 um ; (B) 25 Icm ; (C) 35 lam; (D) 35 im .
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1098staining (Fig . 6, C and D), but immunoreactivity for TGF022
or 03 was not observed . Moderate staining for TGF01 (Fig .
6, A and C), (32, and #3 was also seen in the smooth muscle
of the esophagus and intestine .
Earlier studies have reported that TGF02mRNA is local-
ized to the submucosal layer ofthe embryonic gut (Pelton et
al ., 1989) . TGF02 protein staining was also found in the
basement membrane of this layer (Fig . 7, A andB) . At 13.5
d.p.c., a well demarcated line of staining for TGF02 was evi-
dent just basal to the mucosal (epithelial) layer of the de-
veloping stomach and intestines (Fig. 7, A-C) . TGFS2 im-
munoreactivity was not seen in the muscosal layer of the
stomach nor in the surrounding mesenchymal layers, al-
though staining was observed in the epithelial cells of the in-
testine (Fig . 7 C) .
Previous reports have demonstrated the presence ofTGF01
mRNA in megakaryocytes in the embryonic liver (Wilcox
and Derynck, 1988 ; Lehnert and Akhurst, 1988) and al-
though noTGFO mRNA has been found in liver hepatocytes,
transcripts for TGF02 and 03 have been localized to the cap-
sule surrounding the liver of the 11.5 d .p.c . embryo (Pelton
et al ., 1990x) . Similarly, light staining for TGF01 and (i3
was evident in megakaryocytes of the 12 .5 d.p.c. liver and
TGF03 immunostaining was observed in the liver capsule at
13.5 d.p.c. (Fig . 7 D) . Although light staining for TGF03
was observed in the mesenchymal cells supporting the liver
parenchyma (Fig . 7 D), TGFO 1-3 staining of the hepato-
cytes was not detected .
Heine et al . (1990) have used immunohistochemical anal-
ysis to demonstrate that TGFftI colocalizes in the embryonic
lung with anumber of important ECM proteins . In addition,
earlier reports have shown that TGF0l, /32, and #3 mRNAs
can be detected in the embryonic lung (Pelton et al., 1989,
1990x ; Lehnert and Akhurst, 1988 ; Millan et al ., 1991 ;
Schmid et al ., 1991) . In the adult murine lung, the protein
localization patterns in the proximal airways for all three
TGFss are essentially identical (Pelton et al., 1991) . Cor-
respondingly, TGF0 proteins in the embryonic mouse lung,
showed strikingly similar patterns of expression (Fig . 8,
A-D) . Although slightTGFS 1-3 immunoreactivity was seen
in the epithelium of 17.5 d.p.c . bronchioles, staining for the
TGFss in the airways was seen primarily just basal to the re-
spiratory epithelium (Fig . 8, A-D) . Moreover, staining for
TGF,B 1-3 proteins was present in the smooth muscle cells
in the walls of large blood vessels of the lung in a pattern
similar to that seen in other large vessels of the embryo
(compare Figs. 8,B andC and 4, C andD) . The highest lev-
els ofTGFS expression in the embryonic lung were seen in
late gestation at 17.5-18.5 d.p.c . .
The Embryonic Sense Organs. The lens of the eye is de-
rived from the surface embryonic ectoderm and by 12.5
d.p.c . becomes separate from the epidermis . Distinct layers
Figure 8 . Expression ofTGFss in the 17.5 d.p.c. embryonic lung . (A) Section of a lung in a 17.5 d.p.c. embryo stained with TGF03 antibod-
ies . Strong staining is seen in the bronchioles and large blood vessels (arrows) . (B) Higher power of the section seen inA to show the
TGF03 staining in the subepithelial region of the bronchioles and in the smooth muscle cells of the blood vessel . (C) Similar section to
that inA incubated with TGFS2 antibodies. Staining is seen just basal to the epithelium in the bronchiole as well as in the small blood
vessel (arrows) . (D) High power photomicrograph of a lung section stained with TGF01 antibodies . Low levels of TGF#l were localized
to the epithelium but higher levels were seen in the subepithelium at the base of the epithelial cells (arrows) . b, bronchiole ; bv, blood
vessel ; lp, lung parenchyma; be, bronchiolar epithelium . Bars : (A) 115 um ; (B) 60 gm ; (C) 55,m ; (D) 35 /cm.
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1099Figure 9 Localization of TGFss in the sensory organs . (A) Expression ofTGFS1 in the lens fibers (but not the lens epithelium) of the
17 .5 d.p.c. embryonic eye . (B) Higher power ofA to illustrate the lack of staining at the border between the lens fibers and the lens epithe-
lium . (C) Section through the 14.5 d.p .c . cochlea of the inner ear showing staining for TGF02 in the basement membrane just basal to
the cochlear epithelium (arrow) . (D) Section through the inner ear ofa 13.5 d.p.c . embryo showing TGF03 stainingthroughoutthe cochlear
epithelium . l, lens ; on, optic nerve ; ec, epithelium ofcornea ; p, retinal pigment ; le, lens epithelium ; If, lens fibers ; ce, cochlear epithelium.
Bars : (A) 175 Am ; (B) 45 Am ; (C) 60 Am ; (D) 45 Am .
of lens epithelium and lens fibers have formed by 13 d.p.c.
(Rugh, 1990) . Intense staining for TGFOl was seen in the
lens fibers as early as 14.5 d.p.c . and remained strong
through 17.5 d.p.c. (Fig . 9, A and B) . However, neither the
lens epithelium nor the equatorial region of lens fiber elon-
gation showed TGFS1 expression (Fig . 9, A and B) . TGF/62
and (33 staining was also observed in the lens fibers but was
much weaker than that for TGFO1 . Previous studies have
found the presence of TGF02 mRNA in the embryonic eye
although not in the lens fibers (Millan et al ., 1991) . More-
over, recent reports have found TGFO protein activity (pre-
dominantly TGF02) in the aqueous and vitreous humors of
adult eyes (Connor et al ., 1991 ; Jampel et al ., 1991) indicat-
ing that TGFO expression in the eye continues from the em-
bryo into adulthood .
TGF02 mRNA is present in the ciliated cochlear epithe-
lium of the inner ear (Pelton et al ., 1990x ; Millan et al.,
1991 ; Schmid et al ., 1991) . Immunostaining demonstrated
thatTGF02 protein was also found in the inner ear ; however,
in contrast to theTGF02mRNA, it was localized in the base-
ment membrane just basal to the cochlear epithelium (Fig .
9 C) . This staining pattern was seen as early as 12.5 d.p.c .
and was consistently high through 17.5 d.p.c . . Although
TGF/31 staining in the cochlea was not detected, TGF03 was
localized throughout the cochlear epithelium in the 13.5
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d.p.c . embryo with the highest levels of immunoreactivity
found in the apical region (Fig . 9 D) . Therefore, one of the
most striking differences in immunostaining for TGFO iso-
forms was found in the ear. By 17.5 d .p.c ., TGF03 staining
was no longer present in this epithelium .
The Embryonic Central Nervous System . The central
nervous system (CNS) is unique in that it is one of the first
embryonic systems to arise, yet one of the last to complete
development (Rugh, 1990) . In general, the highest levels of
TGFO immunoreactivity in the embryonic CNS were found
with antibodies to TGFj32 andTGFa3 ; very little staining in
the CNS was observed with TGFM antibodies . By 12.5
d.p.c., the brain and spinal cord are well developed in the
embryo and at this stage, TGF02 staining was already appar-
ent in the meninges which envelop the CNS. The TGF02
staining in the meninges remained strong in the embryo from
13.5 until 17.5 d.p.c . (Fig . 10, A-E) . This is in agreement
with our in situ hybridization data which also shows TGF#2
mRNA expression in the meninges of the embryonic brain
(Pelton et al ., 1989) . In the 17.5 d.p.c. embryo, TGF02 stain-
ing was also found in glia surrounding neurons in the brain
and in spinal cord astrocytes (Fig. 10, F and G) . Although
little TGFM immunoreactivity was seen in the CNS, TGF(33
staining was very strong in the brain, choroid plexus, and
spinal cord (Fig . 10 H) . Both TGF#2 and 03 were localized
1100Figure 10 . Expression ofTGFO proteins in the embryonic central nervous system. Sagittal section through the midbrain region of a 14 .5
d.p.c. embryo demonstrating TGF/92 staining in the meninges surrounding the brain . (b) Higher powerofthe section inAto show staining
in a thin layer of meningeal cells surrounding the brain . (C) Section showing TGF02 expression in themeninges surrounding the dorsal
spinal cord ina 13.5 d.p .c . embryo. (D) Higher power of section in Cto show strong TGF022 staining in the thin layered meninges and
only weak staining in the neurons . (E) Frontal section through the midbrain region ofa 14.5 d.p.c . embryo to demonstrateTGF02 staining
in the meninges. (F) High power micrograph of amidbrain region of a 17.5 d.p.c. embryo to show TGF02 expression in the glial tissue
surrounding theneurons . (G) Section through the 12.5 d.p.c. ventral spinal cord demonstratingTGF02 in astrocytes . (H) Section similar
to Gshowing strong TGF03 staining in the astrocytes ofthe ventral spinal cord. b, brain; m, meninges ; e, epidermis (B) ; sc, spinal cord ;
mb, midbrain ; fv, fourth ventricle ; a, astrocytes ; cc, central canal of spinal cord . Bars : (A) 100 Am ; (B) 85 Am ; (C) 115 Am ; (D) 65
Am; (E) 220 Am ; (F) 30 Am ; (G) 30 pm ; (H) 30 Am .Figure 11. Localization ofTGFps in the embryonic skin . (A) TGFS1 staining in epidermis (arrow) of the 14.5 d.p.c . skin butnot the dermis .
(B) TGFO1 expression in the epidermis (arrow) ofthe 17.5 d.p.c . skin . The dermis is also negative at this stage . (C) Expression ofTGF02
in the 15.5 d.p.c . embryonic skin. Staining is seen in both the dermis and epidermis . (D) Section through skin of a 17.5 d.p .c . embryo
illustrating TGF02 staining primarily in the epidermis at this stage ; only low levels were seen in the dermis . (E) Staining of 17.5 d.p .c .
whisker follicles (arrows) with TGFSI antibodies . e, epidermis ; d, dermis. Bars : (A) 80,,m ; (B) 50Am; (C)35,m; (D) 35,,m ; (E) 50Am .
to spinal cord astrocytes as early as 12.5 d.p.c. (Fig. 10, G
and H) . Whereas, TGF,Q2 staining in the astrocytes was ab-
sent after 13.5 d.p.c ., TGF#3 expression remained consis-
tently high in these cells until late in gestation at 17.5-18.5
d.p.c .
The Embryonic Skin . The skin is formed first as a single
cell layer, the periderm, and begins to differentiate into mul-
tiple layers at -14 d.p.c . (Rugh, 1990) . Significant staining
for the TGFOs was first seen at this stage . At 14.5 d.p.c., in-
tense staining for TGFO1 and TGF03 was seen in the epithe-
lial layer of the skin over the entire body, while only low lev-
els of TGF02 could be detected at this stage (Fig. 11 A) .
TGFfl1 and TGF03 were still localized to the epidermis and
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hair follicles through 17.5 d.p.c . (Fig. 2, A andB and 11, B
and E) . In the 17.5 d.p.c. embryo, TGF01 was also expressed
at very high levels in the keratinized squamous epithelium
of the mouth (Fig . 2, C and D) . Earlier, we reported that
TGF02mRNA is localized to the dermis of 15.5 d.p.c . mouse
embryo skin and showed that by 18.5 d.p.c ., the expression
had switched from the dermis to the epidermis (Pelton et al .,
1989) . In contrast, TGF62 protein in the 15.5 d.p.c . embryo
was present in the dermis, epidermis and hair follicles ofthe
skin (Fig . 11 C) . By 17.5 d.p.c ., most ofthe TGF02 staining
in the dermis had faded but the staining in the epidermis re-
mained strong (compare Fig . 11 C with D) . The highest lev-
els ofTGF02 immunostaining at this stage were seen in the
1102epidermis of the skin, although the hair follicles were also
positive for TGF02 staining.
Discussion
The data presented in these studies demonstrate that TGF01,
TGF02, and TGF03 proteins are expressed during murine
embryogenesis in a temporally and spatially regulated fash-
ion. TGF,6 proteins are differentially expressed in the em-
bryo and show isoform-specific and overlapping localization
patterns. Moreover, in many tissues, the restriction of TGFfl
proteins corresponds with morphogenetic events in the em-
bryo. Comparison of TGFR protein and mRNAlocalizations
is consistent with an intricate pattern of gene transcription,
translation, secretion, storage, and degradation of TGF01,
j32, and /33 during embryogenesis of the mouse. The dis-
parate localization of TGFO mRNAs and proteins in some
tissues and colocalization in others suggests that TGFf1-3
act through both paracrine and autocrine mechanisms in the
morphogenesis of many organs.
In many tissues, TGFO proteins are foundin the same cells
as the TGF0 mRNA. For example, in situhybridization anal-
ysis demonstrates TGFfl 1-3 mRNA expression in the peri-
osteum and osteocytes of developing skeletal tissue (Pelton
et al ., 1990a) in a pattern very similar to the TGFO immuno-
staining presented here. All three TGFO mRNAs (Pelton et
al., 1990a) and proteins colocalized in the osteocytes of the
intramembranous bones of the head and TGF01 immuno-
staining in the perichondrium of developing cartilage was
strikingly similar to the TGF,l31 mRNA pattern (Pelton et al.,
1990a) in this tissue. TGF,62 and /33 also showed examples
of colocalization of mRNA and protein including TGF02 in
the submucosal layer of the gut, the pulp and odontoblasts
of the tooth, the meninges of the CNS, and the skin; and
TGF03 in the capsule of the liver, the choroid plexus, and
the large blood vessels of the embryo. Thus, for the cells in
these tissues, the TGF0s may be working in an autocrine
fashion.
In contrast to this, in many instances, TGF0 mRNA and
proteins were expressed in the same organ and yet were
localized to different, but adjacent, cell types. For example,
in the inner ear, transcripts for TGF02 are found in the coch-
lear epithelium (Pelton et al., 1990a; Schmid et al., 1991;
Millan et al ., 1991), while TGF,62 protein was restricted to
the basement membranejust basal to the cochlear epithelium
(Fig. 9 C). Other examples of differential localization of
TGF0 mRNAs and proteins were seen in the cartilage, brain,
heart, teeth, and skin. It is well established that the TGFfs
are secreted proteins, thus, certain cells may synthesize and
release TGFO proteins into the extracellular matrix of adja-
cent cells which have the potential to respond to these fac-
tors. Thus, our TGFO immunolocalization data, in conjunc-
tion with previous TGF,Q in situ hybridization studies, suggest
that in many tissues, the TGFas act in a paracrine mode. In
support of this model, it has recently been shown that TGF#1
bound to type IV collagen remains biologically active (Vish-
was et al ., 1990) and the ability of latent TGF01 to bind to
heparin-Sepharose suggests thatit contains a specific heparin
binding site (Wakefield et al., 1989). Moreover, the latent
forms of all TGF0s (except TGF02) contain the RGD inte-
grin cellular recognition sequence (Ruoslahti and Piersch-
bacher, 1986). Thus, the extracellular matrix may act as a
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repository for TGF0 proteins. Indeed, at leastone study has
demonstrated that both freshly isolated and commercially
available fibronectins can be contaminated with TGF/3 activ-
ity (Fava and McClure, 1987).
Secretion and subsequent storage of TGF,Qs in the ex-
tracellular matrix may be a primary regulatory step in the
production of mature, biologically active TGFO protein in
vivo. Experiments by Sato et al. (1990) demonstrate that
homotypic cultures of both endothelial cells and smooth
muscle cells secrete TGF0 only in a latent form. However,
if these two cell types are cocultured, a portion of the total
TGFO secreted into the culture medium is activated. This
suggests that in vivo, latent TGFOs may be produced and
secreted by one cell type and activated in conjunction with
an adjacent cell type. Activation of latent TGF,Q may be
through serine proteases (e.g., plasmin; Lyons et al., 1989)
released locally by cells. This idea is supported by the obser-
vation that specific inhibitors ofplasmin blockthe activation
of TGFfl in heterotypic cultures ofendothelial cells and peri-
cytes (Sato and Rifkin, 1989). Furthermore, Saksela and
Rifkin (1990) have proposed a model whereby TGFO regu-
lates the synthesis of plasminogen activator which in turn
regulates the release of bFGF from extracellular matrix. In-
terestingly, a comparison of TGF02 and bFGF staining dur-
ing embryogenesis demonstrates that both of these proteins
are often found in the basement membrane next to an epithe-
lial cell type (Figs. 5, A and B; 7, A-C; 8 C; 9 C; and Gonza-
lez et al., 1990), indicating that these molecules may interact
in vivo.
In some ofthe tissues we examined that express high levels
of TGFO mRNA, very little TGFO protein was observed; the
converse is also true. Other groups have also observed this
phenomenon of TGF0 expression (Lehnert and Akhurst,
1988; Akhurst et al., 1991). This may suggest that some of
the reported mRNA or protein localization is nonspecific;
however, the controls on our experiments have consistently
shown thatthe TGFO probes used forthe in situ hybridization
analysis as well as the TGF0 antibodies used in the immuno-
histochemistry are specific for their respective molecules.
An alternative explanation that is consistent with this data is
suggested by the work of Madisen et al. (1988) who found
that although a prostatic adenocarcinoma cell line produced
more TGFfl mRNA than TGFQ2, there was significantly
more TGF02 protein than TGF01 present in these cells.
Hence, it is possible that some cells transcribe but never
translate a given TGFfl gene. It is known, for example, that
TGF02 has at leastfive different transcripts in the mouse, but
it is not knownhow many are translated into functional pro-
teins (Miller et al., 1990).
To date there have been no reports concerning the em-
bryonic expression of TGF#2 and TGF03 proteins in mam-
mals; however, several papers studying the distribution of
TGF01 have been published (Heine et al., 1987, 1990;
Thompson et al., 1989; Flanders et al., 1989) . Comparison
of our results of TGF01 staining with these previous data
shows that in some tissues the staining patterns were very
similar, while in others they differ. For example, immuno-
staining for TGFOI has been reported in adult murine adre-
nocortical and kidney tubule cells (Thompson et al., 1989)
as well as in murine embryonic chondrocytes (Flanders et
al., 1989) and osteocytes (Heine et al., 1988); these tissues
showed very strong staining for TGF01 in our study as well .
1103Similarly, Jakowlew et al . (1991) observed staining for TGF02,
03, and 04 (and to a lesser extent (31) in avian embryonic
chondrocytes and cardiac myocytes in patterns much like
those seen in the data presented here . Thus, in general, our
results are consistent with the expression of TGFO1 as re-
ported by others (Thompson et al ., 1989 ; Heine et al ., 1988 ;
Flanders, et al., 1988 ; Jakowlew et al ., 1991), however,
we do find some differences between our studies and those
reported by Heine et al . (1988) . For example, the intense
TGFOI staining in the epidermis of the embryonic skin (Figs .
2 B and 11, A-E) and in the epithelium of the gut (Figs . 6,
A-D) was not reported by Heine et al . (1988) . In contrast,
Heine and colleagues found very strong TGFO1 staining in
the atrioventricular valves of the heart which was not seen
in our studies. There are several possible reasons for these
discrepancies between our results and those of Heine et al .
(1988) . The TGF01 antipeptide antibodies used in their ex-
periments were raised against the first 30 amino acids in the
mature region of TGF/31 (Heine et al., 1988), while those
used in our studies were raised against residues 4-19 of the
TGFO1 amino acid sequence . Thus, while the antiTGFOl an-
tibodies used in both studies react with (31, they may recog-
nize different conformations of the protein . For example,
Heine et al . (1988) found that embryos fixed in paraformal-
dehyde did not show immunoreactivity with their antibodies,
while embryos fixed in Bouirfs fixative reacted strongly. In
contrast, all embryos used for our immunohistochemistry
were paraformaldehyde fixed . Alternatively, the possibility
that some antibodies may cross-react with epitopes on other
proteins should also be entertained ; however, Western blot
analysis indicates that specific staining is achieved with each
of the TGFO antibodies used in this study (Fig . 1) .
Yang and Moses (1990) have demonstrated a range of in
vivo cellular events (migration, proliferation, inhibition, an-
giogenesis, etc.) in the chick embryo chorioallantoic mem-
brane in response to exogenously added TGFO1 . A large
body of in vitro evidence also strongly suggests that many
cellular activities critical to morphogenesis (cell prolifera-
tion, cell migration, cell differentiation, extracellular matrix
production, etc.) are mediated by the TGF,Qs (reviewed in
Pelton and Moses, 1990x) . The expression of TGF01, ,Q2,
and ,Q3 during mouse embryogenesis, as presented in our
results, correlates well with these in vivo and in vitro obser-
vations . For example, TGFO1 and (32 are found in the adrenal
cortex of the mouse embryo (Fig . 5, E and F) and human fe-
tal adrenocortical cell differentiation is inhibited by TGF01
(Riopel et al ., 1989) . TGFO proteins also inhibit the growth
of mesangial and proximal tubular cells in the kidney (Avner,
1990), regulate differentiation, proliferation and extracellu-
lar matrix deposition in bone and cartilage cells (Centrella
et al ., 1988) as well as in lung cells (Pelton and Moses,
1990b), mediate transdifferentiation of cells in the em-
bryonic heart (Potts and Runyan, 1989), control the growth
and differentiation of skin cells (Pittelkow et al ., 1988), and
appear to regulate morphogenesis, proliferation, and differ-
entiation in astroglial cells of the central nervous system
(Toru-Delbauffe et al ., 1990) . These are all cell types which
we show to express TGFOs 1-3 during embryogenesis. A ma-
jor challenge is tonow provide evidence that the localization
of TGF0l, /32, and 03 proteins in specific tissues and cells
in the embryo has biological relevance for murine embryonic
development . The most direct in vivo method to achieve this
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endmay be to construct transgenic and/or chimeric animals
which either mis-express or do not express TGFO genes.
Nonetheless, the temporal and spatial expression of TGFOs
1-3 at crucial steps in the morphogenesis of specific organs
in themouse undoubtedly implicates a role for these factors
in the development of the mammalian embryo.
In conclusion, we have generated isoform-specific anti-
bodies which recognize TGFSI, 02, or (33 and have used
them to study the distribution of these three proteins during
murine embryogenesis. We have observed that the expres-
sion patterns for each protein are both temporally and spa-
tially unique . Similarly, these distinct but overlapping pat-
terns of expression are seen for TGFOI, (32, and /33 mRNAs
as well (Pelton et al ., 1990x) . While themRNA and protein
expression patterns do not always strictly coincide, TGFO
protein is often found in cells or extracellular matrix posi-
tioned next to a cell type in which the mRNA is found in
many tissues . This is consistent with the premise that dur-
ing embryonic development, TGFO1, ,Q2, and (i3 may act
through both autocrine and paracrine mechanisms . Cur-
rently, there is little evidence ascribing unique functions for
these three closely related isoforms ofTGFS. The expression
patterns shown in this study of different isoforms ofTGFO
in dissimilar cell types, for example, in the eye and ear, may
imply separate cell-specific functions for each ofthe TGFOs
in vivo . Together with the known biological activities of the
aTGFs, these data support the hypothesis that TGFM, /32,
and (33 are important mediators of cell-cell interaction dur-
ing embryonic development andmay offer insight into an ex-
planation for the evolutionary persistence of these very
closely related proteins .
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